How India Exports Griseofulvin to the World

In the United States, griseofulvin is approved for the treatment of fungal infections of the skin, hair, and nails. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for griseofulvin, indicating a well-established generic market. The presence of 188 active Indian exporters underscores the competitive landscape and the significant role of Indian manufacturers in supplying griseofulvin to the U.S. market.

As of March 2026, there are no active import alerts or significant regulatory actions against griseofulvin products from India, suggesting compliance with FDA standards. The regulatory pathway for griseofulvin involves submission of an ANDA, demonstrating bioequivalence to the reference listed drug, without the need for extensive clinical trials.

In the European Union, marketing authorization for griseofulvin is granted by national competent authorities, as it is not centrally authorized by the European Medicines Agency (EMA). The UK's Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval process within the United Kingdom. Manufacturers exporting to these regions must comply with Good Manufacturing Practice (GMP) requirements as outlined in EU Directive 2003/94/EC. This includes adherence to quality standards in manufacturing processes, quality control, and product testing to ensure safety and efficacy.

Griseofulvin is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in treating fungal infections. The 24th edition of the list, published in September 2025, continues to feature griseofulvin, reflecting its recognized therapeutic value. (who.int) The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

In India, griseofulvin is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, griseofulvin is not listed under the Drugs (Prices Control) Order (DPCO), and thus, its price is not subject to government-mandated ceilings. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations and quality standards.

The primary patents for griseofulvin have long expired, with the active pharmaceutical ingredient (API) patents expiring in the mid-1970s. This has led to a robust generic market with multiple manufacturers producing and exporting the drug. The absence of active patents facilitates competitive pricing and widespread availability, benefiting both exporters and consumers.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming the inclusion of griseofulvin in the 24th edition published in September 2025. (who.int) This underscores the ongoing global recognition of griseofulvin's therapeutic importance.

In January 2026, the Indian Ministry of Health and Family Welfare issued new guidelines to streamline the export NOC process for pharmaceutical products, including griseofulvin. These guidelines aim to reduce administrative burdens and expedite export approvals, benefiting the 188 active Indian exporters supplying griseofulvin to international markets.

Additionally, in February 2026, the NPPA conducted a review of essential medicines pricing but did not include griseofulvin under the DPCO, allowing market-driven pricing to continue. This decision reflects the competitive nature of the griseofulvin market and the absence of significant pricing concerns.

These developments highlight the dynamic regulatory environment surrounding griseofulvin, with ongoing efforts to balance accessibility, affordability, and compliance with international standards.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). Approximately 60–70% of India's API and KSM requirements are imported from China. This dependency poses a significant risk, as any disruption in Chinese supply chains can directly impact India's pharmaceutical production capabilities.

Recent environmental regulations in China have led to the shutdown of several chemical manufacturing units, causing supply shortages and price increases for KSMs. For instance, in July 2018, the closure of Chinese companies resulted in supply chain disruptions for Indian pharmaceutical manufacturers. Such events underscore the vulnerability of India's pharmaceutical supply chain due to its reliance on Chinese raw materials.

The export market for Griseofulvin is highly concentrated, with the top five exporters accounting for 76.6% of the total export value. LINCOLN PHARMACEUTICALS LTD alone holds a 62.0% share, exporting $22.4 million worth of Griseofulvin. This high concentration poses a single-source risk, as any operational or quality issues within these leading companies could significantly disrupt the supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic production of critical APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, reducing import dependence. However, the effectiveness of this initiative in diversifying the supplier base for Griseofulvin remains to be seen.

Geopolitical tensions and shipping disruptions can significantly impact the pharmaceutical supply chain. For instance, the Red Sea and the Strait of Hormuz are critical maritime routes for global trade. Any instability in these regions can delay shipments and increase transportation costs. Additionally, ongoing U.S.-China tensions have led to increased scrutiny and potential tariffs on pharmaceutical imports, affecting the cost and availability of raw materials.

Regulatory bodies like the FDA and EMA have reported drug shortages due to supply chain disruptions. The FDA's Drug Shortages Database indicates that manufacturing and quality issues, often stemming from supply chain vulnerabilities, are common causes of drug shortages. Such shortages highlight the need for robust supply chain management to ensure the continuous availability of essential medications like Griseofulvin.

• Diversify Supplier Base: Encourage the development of multiple suppliers for Griseofulvin to reduce dependency on a few key exporters.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for APIs and KSMs to decrease reliance on imports, particularly from China.

• Strengthen Regulatory Compliance: Ensure that all suppliers adhere to stringent quality standards to prevent disruptions due to regulatory non-compliance.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain.

• Develop Contingency Plans: Create comprehensive contingency plans to address potential supply chain disruptions, including alternative sourcing strategies and inventory management practices.

RISK_LEVEL: MEDIUM